Skip to main content

Theranos Inc founder Elizabeth Holmes and the embattled blood-testing company’s former president were indicted on charges that they engaged in schemes to defraud investors, doctors and patients, the U.S. Justice Department announced on Friday.

The charges against Holmes, 34, and Ramesh “Sunny” Balwani, 53, were announced shortly after the privately-held company said that she was stepping down as its chief executive officer.

Prosecutors said that Holmes and Balwani used advertising and solicitations to encourage doctors and patients to use its blood testing laboratory services despite knowing the company could not produce accurate and reliable results consistently.

Story continues below advertisement

The indictment also alleged that Holmes and Balwani made numerous misrepresentations about Theranos’ financial condition and futures prospects.

Each defendant faces two counts of conspiracy to commit wire fraud and nine counts of wire fraud. Prosecutors said both made initial court appearances on Friday before a federal magistrate judge in San Jose.

The criminal charges came after Holmes in March settled civil fraud charges brought by the U.S. Securities and Exchange Commission under which she was barred from serving as an officer or director of a public company for 10 years.

In a statement, Theranos said Holmes would remain chair of the company’s board and David Taylor, the firm’s general counsel, has been appointed its CEO.

Lawyers for Holmes and Balwani could not be immediately reached for comment.

Once called the Steve Jobs of biotech, Holmes started Theranos at the age of 19 and the company was soon considered a Silicon Valley darling with a $9 billion valuation based on its promise to disrupt the laboratory testing business.

Theranos claimed its innovative blood testing device would give quicker and more reliable results than standard blood tests using just a single drop of blood from a finger stick.

Story continues below advertisement

In 2015, the Wall Street Journal reported that Theranos’ devices were flawed and inaccurate, setting off a downward spiral for the company that had bagged investors including venture capital firm DFJ, Walgreens, media mogul Rupert Murdoch and Oracle co-founder Larry Ellison.

Report an error
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter